Considerations in the management of elderly patients with chronic myeloid leukemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 12, Issue 1, 2012, Pages 12-19

  Seiter, Karen ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Dasatinib; Geriatric oncology; Imatinib; Nilotinib; Tyrosine kinase inhibitors

Indexed keywords

ALPHA INTERFERON; ANTACID AGENT; ANTHRACYCLINE; DASATINIB; HYDROXYUREA; IMATINIB; NILOTINIB; PROTON PUMP INHIBITOR;

ABDOMINAL PAIN; AGED; ANEMIA; ANXIETY; ARTHRALGIA; ASTHENIA; BLEEDING; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CARDIOVASCULAR DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL DECISION MAKING; DATA ANALYSIS; DIARRHEA; DIZZINESS; DRUG MEGADOSE; DRUG SAFETY; DYSPEPSIA; DYSPNEA; EDEMA; GERIATRIC PATIENT; HEALTH INSURANCE; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; LOW DRUG DOSE; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; NAUSEA AND VOMITING; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL (TOPIC); RASH; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; SOCIAL STATUS; THROMBOCYTOPENIA;

AGE FACTORS; AGED; AGED, 80 AND OVER; HEALTH SERVICES FOR THE AGED; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROGNOSIS; PROTEIN KINASE INHIBITORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84856913237     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.10.001     Document Type: Review

References (54)

1. P.C. Nowell, D.A. Hungerford Chromosome studies on normal and leukemic human leukocytes J Natl Cancer Inst 25 1960 85 109
2. J.D. Rowley Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining Nature 243 1973 290 293
3. N. Heisterkamp, K. Stam, J. Groffen Structural organization of the bcr gene and its role in the Ph' translocation Nature 315 1985 758 761 (Pubitemid 15022931)
4. W.S. Pear, J.P. Miller, L. Xu Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow Blood 92 1998 3780 3792 (Pubitemid 28525205)
5. M. Rohrbacher, J. Hasford Epidemiology of chronic myeloid leukaemia (CML) Best Pract Res Clin Haematol 22 2009 295 302
6. S.F. Altekruse, C.L. Kosary, M. Krapcho et al. SEER Cancer Statistics Review1975-2007 Bethesda (MD): National Cancer Institute http://seer.cancer.gov/ csr/1975-2007/ Accessed: September 30, 2011
7. A. Fefer, M.A. Cheever, E.D. Thomas Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin N Engl J Med 300 1979 333 337 (Pubitemid 9114885)
8. M. Talpaz, K.B. McCredie, G.M. Mavligit Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia Blood 62 1983 689 692 (Pubitemid 13001704)
9. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia The Italian Cooperative Study Group on Chronic Myeloid Leukemia N Engl J Med 330 1994 820 825
10. N.C. Allan, S.M. Richards, P.C. Shepherd UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia Lancet 345 1995 1392 1397
11. Chronic Myelogenous Leukemia National Comprehensive Cancer Network Clinical Practice Guidelines in Oncologyv.2.2012 National Comprehensive Cancer Network [Web site] http://www.nccn.org/professionals/physician-gls/f-guidelines. asp Accessed: October 19, 2011
12. C. Preudhomme, J. Guilhot, F.E. Nicolini Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia N Engl J Med 363 2010 2511 2521
13. M. Robin, P. Guardiola, A. Devergie A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors Leukemia 19 2005 1613 1620 (Pubitemid 43090406)
14. B.J. Druker, M. Talpaz, D.J. Resta Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 2001 1031 1037 (Pubitemid 32267972)
15. C. Gambacorti-Passerini, L. Antolini, F.X. Mahon Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib J Natl Cancer Inst 103 2011 553 561
16. J.A. Foster, G.D. Salinas, D. Mansell How does older age influence oncologists' cancer management? Oncologist 15 2010 584 592
17. C. Bouchardy, E. Rapiti, S. Blagojevic Older female cancer patients: importance, causes, and consequences of undertreatment J Clin Oncol 25 2007 1858 1869 (Pubitemid 46854419)
18. C.L. Wiggins, L.C. Harlan, H.E. Nelson Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia Am J Med 123 2010 764 e1-9
19. M. Bjorkholm, L. Ohm, S. Eloranta Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008 J Clin Oncol 29 2011 2514 2520
20. J.E. Sokal, E.B. Cox, M. Baccarani Prognostic discrimination in "good-risk" chronic granulocytic leukemia Blood 63 1984 789 799 (Pubitemid 14141296)
21. H.M. Kantarjian, M.J. Keating, K.B. McCredie Old age: a sign of poor prognosis in patients with chronic myelogenous leukemia South Med J 80 1987 1228 1232 (Pubitemid 17160779)
22. J. Hasford, M. Pfirrmann, R. Hehlmann A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group J Natl Cancer Inst 90 1998 850 858 (Pubitemid 28280552)
23. J. Cortes, M. Talpaz, S. O'Brien Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia Cancer 98 2003 1105 1113 (Pubitemid 37099894)
24. G. Gugliotta, F. Castagnetti, F. Palandri Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party Blood 117 2011 5591 5599
25. R. Latagliata, M. Breccia, I. Carmosino Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment Leuk Res 29 2005 287 291
26. R. Latagliata, M. Breccia, F. Castagnetti Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib Leuk Res 35 2011 1164 1169
27. R. Latagliata, D. Ferrero, F. Cavazzini Imatinib in very elderly CML patients: what can we achieve? Blood (ASH Annual Meeting Abstracts) 116 2010 1229
28. P.D. le Coutre, A. Turkina, D.-W. Kim Efficacy and safety of nilotinib in elderly patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP): a sub-analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) study Blood (ASH Annual Meeting Abstracts) 114 2009 3286
29. J.H. Lipton, P.D. le Coutre, J. Wang Nilotinib in elderly chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: efficacy and safety analysis Blood (ASH Annual Meeting Abstracts) 112 2008 3233
30. G. Rosti, I. Iacobucci, S. Bassi Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party Haematologica 92 2007 101 105 (Pubitemid 46232662)
31. F.M. Sanchez-Guijo, S. Duran, J. Galende Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study Leuk Res 35 2011 1184 1187
32. O.M. Sheehy, A.E. Irvine, R.J. Cuthbert Use of imatinib mesylate in elderly patients in Northern Ireland: evidence of comparable haematological and molecular responses to younger patients Hematology 13 2008 133 136
33. Larson RA, Kim D, Rosti G, et al. Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up. Poster presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 3-7, 2011; Chicago, IL.
34. R. Porrini, E. Montefusco, R. Latagliata Low-dose dasatinib as front-line therapy for elderly (>60 years) patients with CML Blood (ASH Annual Meeting Abstracts) 116 2010 2293
35. J. Hasford, M. Baccarani, V. Hoffmann Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score Blood 118 2011 686 692
36. S.G. O'Brien, F. Guilhot, R.A. Larson Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 2003 994 1004 (Pubitemid 36302244)
37. G. Saglio, D.W. Kim, S. Issaragrisil Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia N Engl J Med 362 2010 2251 2259
38. H. Kantarjian, N.P. Shah, A. Hochhaus Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 362 2010 2260 2270
39. H.M. Kantarjian, F.J. Giles, K.N. Bhalla Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results Blood 117 2011 1141 1145
40. N.P. Shah, H.M. Kantarjian, D.W. Kim Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia J Clin Oncol 26 2008 3204 3212
41. J.A. Driver, L. Djousse, G. Logroscino Incidence of cardiovascular disease and cancer in advanced age: prospective cohort study BMJ 337 2008 a2467
42. K.C. Meyer Aging Proc Am Thorac Soc 2 2005 433 439 (Pubitemid 43128039)
43. S. Saussele, N. Pletsch, M. Lauseker Therapy with imatinib in elderly CML patients (>65 years): results of the German CML-Study IV Blood (ASH Annual Meeting Abstracts) 116 2010 3411
44. ® (nilotinib) [prescribing information] 2010 Novartis Pharmaceuticals Corporation East Hanover, NJ
45. H.J. Khoury, J.E. Cortes, H. Kantarjian Safety and efficacy of dasatinib (DAS) vs. imatinib (IM) by baseline comorbidity in patients with chronic myeloid leukemia in chronic phase (CML-CP): analysis of the DASISION trial Blood (ASH Annual Meeting Abstracts) 116 2010 3421
46. ® (dasatinib) [prescribing information] 2010 Bristol-Myers Squibb Company Princeton, NJ
47. G. Saglio, R.A. Larson, T.P. Hughes Efficacy and safety of nilotinib in chronic phase (CP) chronic myeloid leukemia (CML) patients (pts) with type 2 diabetes in the ENESTnd trial Blood (ASH Annual Meeting Abstracts) 116 2010 3430
48. National Center for Health Statistics Health, United States, 2010: With Special Feature on Death and Dying 2011 U.S. Government Printing Office Hyattsville (MD), Washington, D.C. 1 536
49. N.P. van Erp, H. Gelderblom, H.J. Guchelaar Clinical pharmacokinetics of tyrosine kinase inhibitors Cancer Treat Rev 35 2009 692 706
50. ® (imatinib mesylate) [prescribing information] 2010 Novartis Pharmaceuticals Corporation East Hanover, NJ
51. D. Russo, G. Martinelli, M. Malagola One year of intermittent imatinib (IM) treatment (interim) maintains the complete cytogenetic response (CCgR) previously achieved with standard IM therapy in elderly (< 65 years) Ph+ CML patientsEudraCT Number 2007-005102-42, ClinicalTrials.gov NCT 00858806 Blood (ASH Annual Meeting Abstracts) 116 21 2010 3412
52. Chronic Myelogenous Leukemia National Comprehensive Cancer Network Clinical Practice Guidelines in Oncologyv.2.2011 National Comprehensive Cancer Network [Web site] http://www.nccn.org/professionals/physician-gls/PDF/cml.pdf Accessed January 24, 2011
53. M. Baccarani, F. Castagnetti, G. Gugliotta Response definitions and European LeukemiaNet management recommendations Best Pract Res Clin Haematol 22 2009 331 341
54. J. Xu, K.D. Kochanek, S.L. Murphy et al. Deaths: final data for 2007 Natl Vital Statistics Rep 58 2010 1 135